For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Actinic keratosis (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. It's most commonly found on the face, lips, ears, back of your hands, forearms, scalp or neck.
Scope of the Report:
The classification of Actinic Keratosis Treatment includes Destructive Treatment, Photodynamic Therapy, Topical Medications and Other, and the Most of Actinic Keratosis Treatment is Destructive Treatment, and proportion of Destructive Treatment in 2017 is about 81.4%. Cryotherapy was the most ordinarily looked for treatment by clinicians. Notwithstanding, better clinical consequences of photodynamic treatment and developing inclination for medications in view of medication gadget mix have asked both parental figures and patients to choose novel treatment techniques that offer both propelled adequacy, stylish advantages and decreased danger of future malignancies.
Actinic Keratosis Treatment is widely used in hospital, clinic and other. The most proportion of Actinic Keratosis Treatment is used in clinic, and the proportion in 2017 is about 63%.
Market competition is intense. DUSA Pharmaceuticals, Novartis, Perrigo, LEO Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. The major company of Photodynamic Therapy for Actinic Keratosis Treatment is DUSA Pharmaceuticals, Galderma (Nestle), Biofrontera in USA.
The global Actinic Keratosis Treatment market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Actinic Keratosis Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Actinic Keratosis Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Actinic Keratosis Treatment market by product type and applications/end industries.
Market Segment by Companies, this report covers
- DUSA Pharmaceuticals
- Novartis
- Perrigo
- LEO Pharma
- Bausch Health
- Taro Pharmaceutical
- Galderma (Nestle)
- Biofrontera
- Almirall
- Tolmar Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Destructive Treatment
- Photodynamic Therapy
- Topical Medications
- Other
Market Segment by Applications, can be divided into
- Hospital
- Clinic
- Other